FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897581535> ?p ?o ?g. }

• W2897581535 endingPage "3360" @default.
• W2897581535 startingPage "3353" @default.
• W2897581535 abstract "Purpose To determine the activity of pembrolizumab as neoadjuvant immunotherapy before radical cystectomy (RC) for muscle-invasive bladder carcinoma (MIBC) for which standard cisplatin-based chemotherapy is poorly used. Patients and Methods In the PURE-01 study, patients had a predominant urothelial carcinoma histology and clinical (c)T≤3bN0 stage tumor. They received three cycles of pembrolizumab 200 mg every 3 weeks before RC. The primary end point in the intention-to-treat population was pathologic complete response (pT0). Biomarker analyses included programmed death-ligand 1 (PD-L1) expression using the combined positive score (CPS; Dako 22C3 pharmDx assay), genomic sequencing (FoundationONE assay), and an immune gene expression assay. Results Fifty patients were enrolled from February 2017 to March 2018. Twenty-seven patients (54%) had cT3 tumor, 21 (42%) cT2 tumor, and two (4%) cT2-3N1 tumor. One patient (2%) experienced a grade 3 transaminase increase and discontinued pembrolizumab. All patients underwent RC; there were 21 patients with pT0 (42%; 95% CI, 28.2% to 56.8%). As a secondary end point, downstaging to pT<2 was achieved in 27 patients (54%; 95% CI, 39.3% to 68.2%). In 54.3% of patients with PD-L1 CPS ≥ 10% (n = 35), RC indicated pT0, whereas RC indicated pT0 in only 13.3% of those with CPS < 10% (n = 15). A significant nonlinear association between tumor mutation burden (TMB) and pT0 was observed, with a cutoff at 15 mutations/Mb. Expression of several genes in pretherapy lesions was significantly different between pT0 and non-pT0 cohorts. Significant post-therapy changes in the TMB and evidence of adaptive mechanisms of immune resistance were observed in residual tumors. Conclusion Neoadjuvant pembrolizumab resulted in 42% of patients with pT0 and was safely administered in patients with MIBC. This study indicates that pembrolizumab could be a worthwhile neoadjuvant therapy for the treatment of MIBC when limited to patients with PD-L1–positive or high-TMB tumors." @default.
• W2897581535 created "2018-10-26" @default.
• W2897581535 creator A5001956192 @default.
• W2897581535 creator A5012466586 @default.
• W2897581535 creator A5016829295 @default.
• W2897581535 creator A5031550729 @default.
• W2897581535 creator A5032009066 @default.
• W2897581535 creator A5034916881 @default.
• W2897581535 creator A5036320874 @default.
• W2897581535 creator A5053320162 @default.
• W2897581535 creator A5053497806 @default.
• W2897581535 creator A5054660525 @default.
• W2897581535 creator A5058078884 @default.
• W2897581535 creator A5058849092 @default.
• W2897581535 creator A5059157811 @default.
• W2897581535 creator A5061623935 @default.
• W2897581535 creator A5062688482 @default.
• W2897581535 creator A5078798686 @default.
• W2897581535 creator A5078919686 @default.
• W2897581535 creator A5080811290 @default.
• W2897581535 creator A5083331837 @default.
• W2897581535 creator A5086507632 @default.
• W2897581535 creator A5088559019 @default.
• W2897581535 creator A5088809839 @default.
• W2897581535 creator A5090061046 @default.
• W2897581535 date "2018-12-01" @default.
• W2897581535 modified "2023-10-17" @default.
• W2897581535 title "Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study" @default.
• W2897581535 cites W1595765532 @default.
• W2897581535 cites W1893588230 @default.
• W2897581535 cites W1972027031 @default.
• W2897581535 cites W2046698356 @default.
• W2897581535 cites W2073175347 @default.
• W2897581535 cites W2113156769 @default.
• W2897581535 cites W2152762320 @default.
• W2897581535 cites W2160981405 @default.
• W2897581535 cites W2213492263 @default.
• W2897581535 cites W2289712604 @default.
• W2897581535 cites W2299181842 @default.
• W2897581535 cites W2330694848 @default.
• W2897581535 cites W2398131194 @default.
• W2897581535 cites W2462649057 @default.
• W2897581535 cites W2588916311 @default.
• W2897581535 cites W2606495925 @default.
• W2897581535 cites W2619249519 @default.
• W2897581535 cites W2655262992 @default.
• W2897581535 cites W2760661635 @default.
• W2897581535 cites W2761575992 @default.
• W2897581535 cites W2764336049 @default.
• W2897581535 cites W2782183686 @default.
• W2897581535 cites W2788431960 @default.
• W2897581535 cites W2798160602 @default.
• W2897581535 cites W2800613296 @default.
• W2897581535 cites W2802899563 @default.
• W2897581535 cites W2809685212 @default.
• W2897581535 cites W2889838670 @default.
• W2897581535 cites W2892310850 @default.
• W2897581535 doi "https://doi.org/10.1200/jco.18.01148" @default.
• W2897581535 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30343614" @default.
• W2897581535 hasPublicationYear "2018" @default.
• W2897581535 type Work @default.
• W2897581535 sameAs 2897581535 @default.
• W2897581535 citedByCount "424" @default.
• W2897581535 countsByYear W28975815352018 @default.
• W2897581535 countsByYear W28975815352019 @default.
• W2897581535 countsByYear W28975815352020 @default.
• W2897581535 countsByYear W28975815352021 @default.
• W2897581535 countsByYear W28975815352022 @default.
• W2897581535 countsByYear W28975815352023 @default.
• W2897581535 crossrefType "journal-article" @default.
• W2897581535 hasAuthorship W2897581535A5001956192 @default.
• W2897581535 hasAuthorship W2897581535A5012466586 @default.
• W2897581535 hasAuthorship W2897581535A5016829295 @default.
• W2897581535 hasAuthorship W2897581535A5031550729 @default.
• W2897581535 hasAuthorship W2897581535A5032009066 @default.
• W2897581535 hasAuthorship W2897581535A5034916881 @default.
• W2897581535 hasAuthorship W2897581535A5036320874 @default.
• W2897581535 hasAuthorship W2897581535A5053320162 @default.
• W2897581535 hasAuthorship W2897581535A5053497806 @default.
• W2897581535 hasAuthorship W2897581535A5054660525 @default.
• W2897581535 hasAuthorship W2897581535A5058078884 @default.
• W2897581535 hasAuthorship W2897581535A5058849092 @default.
• W2897581535 hasAuthorship W2897581535A5059157811 @default.
• W2897581535 hasAuthorship W2897581535A5061623935 @default.
• W2897581535 hasAuthorship W2897581535A5062688482 @default.
• W2897581535 hasAuthorship W2897581535A5078798686 @default.
• W2897581535 hasAuthorship W2897581535A5078919686 @default.
• W2897581535 hasAuthorship W2897581535A5080811290 @default.
• W2897581535 hasAuthorship W2897581535A5083331837 @default.
• W2897581535 hasAuthorship W2897581535A5086507632 @default.
• W2897581535 hasAuthorship W2897581535A5088559019 @default.
• W2897581535 hasAuthorship W2897581535A5088809839 @default.
• W2897581535 hasAuthorship W2897581535A5090061046 @default.
• W2897581535 hasBestOaLocation W28975815351 @default.
• W2897581535 hasConcept C121608353 @default.
• W2897581535 hasConcept C126322002 @default.
• W2897581535 hasConcept C126894567 @default.
• W2897581535 hasConcept C143998085 @default.

• next